Oppenheimer Reiterates “Outperform” Rating for LeMaitre Vascular (NASDAQ:LMAT)

LeMaitre Vascular (NASDAQ:LMAT)‘s stock had its “outperform” rating reissued by stock analysts at Oppenheimer in a report released on Friday, Benzinga reports. They presently have a $93.00 target price on the medical instruments supplier’s stock, up from their prior target price of $90.00. Oppenheimer’s target price would indicate a potential downside of 1.98% from the company’s previous close.

Several other equities analysts have also commented on the stock. JMP Securities increased their price objective on shares of LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a research report on Tuesday, August 20th. Cantor Fitzgerald began coverage on shares of LeMaitre Vascular in a research report on Tuesday, October 15th. They set a “neutral” rating and a $96.00 target price on the stock. StockNews.com cut shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Barrington Research lifted their price target on LeMaitre Vascular from $92.00 to $93.00 and gave the company an “outperform” rating in a report on Friday. Finally, Lake Street Capital initiated coverage on shares of LeMaitre Vascular in a research report on Friday, August 2nd. They issued a “buy” rating and a $105.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $94.57.

LeMaitre Vascular Trading Up 7.3 %

NASDAQ LMAT opened at $94.88 on Friday. The company’s 50 day moving average is $89.59 and its two-hundred day moving average is $83.11. The stock has a market cap of $2.13 billion, a price-to-earnings ratio of 51.85, a PEG ratio of 2.32 and a beta of 0.89. LeMaitre Vascular has a 12 month low of $45.96 and a 12 month high of $101.67.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings data on Thursday, October 31st. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.05. The business had revenue of $54.82 million during the quarter, compared to analyst estimates of $53.50 million. LeMaitre Vascular had a net margin of 19.40% and a return on equity of 13.39%. The company’s revenue was up 15.6% on a year-over-year basis. During the same period last year, the firm posted $0.33 EPS. Sell-side analysts forecast that LeMaitre Vascular will post 1.86 EPS for the current year.

Insiders Place Their Bets

In other LeMaitre Vascular news, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction that occurred on Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares in the company, valued at approximately $1,158,335.98. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 10.79% of the stock is owned by insiders.

Hedge Funds Weigh In On LeMaitre Vascular

A number of large investors have recently bought and sold shares of LMAT. Conestoga Capital Advisors LLC grew its stake in LeMaitre Vascular by 1.9% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,978,351 shares of the medical instruments supplier’s stock valued at $183,769,000 after acquiring an additional 36,850 shares during the period. Vanguard Group Inc. increased its position in LeMaitre Vascular by 0.3% during the first quarter. Vanguard Group Inc. now owns 1,553,834 shares of the medical instruments supplier’s stock worth $103,112,000 after purchasing an additional 4,964 shares during the last quarter. Copeland Capital Management LLC increased its holdings in shares of LeMaitre Vascular by 1.0% during the 3rd quarter. Copeland Capital Management LLC now owns 1,163,392 shares of the medical instruments supplier’s stock worth $108,068,000 after buying an additional 11,318 shares during the last quarter. Congress Asset Management Co. raised its position in LeMaitre Vascular by 2.6% in the third quarter. Congress Asset Management Co. now owns 709,316 shares of the medical instruments supplier’s stock valued at $65,888,000 after purchasing an additional 18,295 shares during the period. Finally, Driehaus Capital Management LLC raised its holdings in LeMaitre Vascular by 52.2% in the 2nd quarter. Driehaus Capital Management LLC now owns 264,217 shares of the medical instruments supplier’s stock valued at $21,740,000 after buying an additional 90,573 shares during the period. Institutional investors and hedge funds own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.